Published in PLoS One on February 10, 2015
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (2012) 12.00
Multimodality molecular imaging of tumor angiogenesis. J Nucl Med (2008) 3.99
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer (2011) 3.88
Transport of molecules across tumor vasculature. Cancer Metastasis Rev (1987) 3.67
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol (2006) 3.19
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol (2010) 2.96
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res (2012) 2.78
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol (2004) 2.13
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol (2007) 1.79
Tracer kinetic modelling in MRI: estimating perfusion and capillary permeability. Phys Med Biol (2011) 1.75
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.71
Monitoring chemotherapy and radiotherapy of solid tumors. Eur J Nucl Med Mol Imaging (2006) 1.47
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res (2000) 1.47
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs (2009) 1.42
Optimal k-space sampling for dynamic contrast-enhanced MRI with an application to MR renography. Magn Reson Med (2009) 1.42
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Quantification of cerebral blood flow, cerebral blood volume, and blood-brain-barrier leakage with DCE-MRI. Magn Reson Med (2009) 1.28
New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors. Magn Reson Med (2004) 1.18
Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther (2013) 1.15
Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101. Neoplasia (2004) 1.13
Non-invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost (2013) 1.12
Novel agents and approaches for advanced renal cell carcinoma. J Urol (2012) 1.11
Phenotyping of tumor biology in patients by multimodality multiparametric imaging: relationship of microcirculation, alphavbeta3 expression, and glucose metabolism. J Nucl Med (2010) 1.07
Perfusion MR imaging of extracranial tumor angiogenesis. Top Magn Reson Imaging (2004) 1.02
The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging (2013) 1.02
Imaging of tumor angiogenesis: current approaches and future prospects. Curr Pharm Des (2006) 1.00
Tracer-kinetic modeling of dynamic contrast-enhanced MRI and CT: a primer. J Pharmacokinet Pharmacodyn (2013) 0.96
RECIST rules. Cancer Imaging (2012) 0.96
The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors. Invest Radiol (2005) 0.95
mTOR inhibitors in breast cancer: a systematic review. Gynecol Oncol (2012) 0.94
Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation. PLoS One (2013) 0.93
Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. Br J Surg (2006) 0.92
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study. AJR Am J Roentgenol (2012) 0.88
New macromolecular polymeric MRI contrast agents for application in the differentiation of cancer from benign soft tissues. J Magn Reson Imaging (2008) 0.88
Clinical and imaging tools in the early diagnosis of prostate cancer, a review. JBR-BTR (2010) 0.88
Anti-angiogenic therapies for metastatic colorectal cancer: current and future perspectives. World J Gastroenterol (2013) 0.85
Dynamic (18)F-FDG-PET for monitoring treatment effect following anti-angiogenic therapy in triple-negative breast cancer xenografts. Acta Oncol (2013) 0.84
Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner. J Nucl Med (2012) 0.84
Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol (2014) 0.83
Molecular imaging with dynamic contrast-enhanced computed tomography. Clin Radiol (2010) 0.82
The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res (2012) 0.82
Prognostic value of different CT measurements in early therapy response evaluation in patients with metastatic colorectal cancer. Cancer Imaging (2012) 0.81
Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins. PLoS One (2014) 0.81
[Multiparametric imaging with simultaneous MR/PET. Methodological aspects and possible clinical applications]. Radiologe (2013) 0.79
Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clin Colorectal Cancer (2011) 0.78
[Preclinical imaging in animal models of radiation therapy]. Radiologe (2012) 0.77
Functional response imaging following neoadjuvant therapy for rectal cancer. Surg Technol Int (2009) 0.77
[New molecular targeting drugs for metastatic colorectal cancer]. Nihon Rinsho (2014) 0.76
DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation. Acta Radiol (2014) 0.76